A Phase 1 Study of LY2874455 in Participants With Advanced Cancer

Lilly

Status and phase: Completed; Phase 1

Conditions: Advanced Cancer

Treatments: Drug: FGF Receptor; Drug: Phosphate Binders

Study type: Interventional

Funder types: Industry

Identifiers

NCT01212107

I4R-MC-FGAA (Other Identifier)

13843

Details and patient eligibility

About

The study is to determine the recommended Phase 2 regimen of study drug that may be safely administered to participants with advanced and or metastatic cancer. The study consists of two parts: a dose escalation and a dose confirmation.

Full description

Phase 1, first human dose study

Enrollment: 94 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Have histological or cytological evidence of a diagnosis of cancer (solid tumors, lymphoma, or chronic lymphocytic leukemia) that is advanced and/or metastatic and for which all standard therapies have failed

• Have the presence of measurable or non-measurable disease

• Have given written informed consent prior to any study-specific procedures

• Have adequate organ function including:

  • Hematologic: Absolute neutrophil count (ANC) equal to or greater than 1.5 x 10(9)/L platelets equal to or greater than 100 x 10(9)/L, and hemoglobin equal to or greater than 8 g/dL. Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin until 14 days after the erythrocyte transfusion
  • Hepatic: Bilirubin equal to or less than 1.5 times upper limits of normal (ULN), alanine transaminase (ALT), and aspartate transaminase (AST) equal to or less than 2.5 times ULN. If the liver has tumor involvement, AST and ALT equaling equal to or less than 5 times ULN are acceptable
  • Renal: Serum creatinine less than or equal to 1.2 times ULN or calculated creatinine clearance greater than or equal to 60 milliliters per minute using the Standard Cockcroft and Gault Creatinine Clearance Calculation
  • Calcium and phosphate less than or equal to 1.1 times ULN

• Have a performance status of 0, 1, or 2 on the Eastern Cooperative Oncology Group (ECOG) scale

• Have discontinued chemotherapy and cancer-related hormonal therapy with commercially available agents for at least 21 days (6 weeks for mitomycin-C or nitrosoureas) and radiotherapy for at least 14 days prior to study enrollment and recovered from the acute effects of therapy. Hormone refractory prostate cancer participants receiving gonadotropin releasing hormone (GnRH) agonist therapy or breast cancer participants on antiestrogen therapy (for example, an aromatase inhibitor) prior to entrance on the study may have that treatment continued while they are enrolled in the study

• Females with childbearing potential must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drug. Males and females with reproductive potential must agree to use 2 medically approved contraceptive methods during the trial and for 3 months following the last dose of study drug. Female participants must agree to use 2 medically acceptable methods of contraception, 1 being an oral contraceptive, dermal patch, or progestin (implantation or injection), and the other being a medically acceptable barrier method; alternatively, 2 medically acceptable barrier methods may be used. Medically acceptable barrier methods of contraception that may be used by the participant and/or his/her partner include: abstinence; diaphragm with spermicide; intrauterine device (IUD); condom together with foam, spermicide, or vaginal spermicidal suppository. Prohibited methods include the rhythm method, withdrawal, condoms alone, or diaphragm alone

• Have an estimated life expectancy of greater than or equal to 12 weeks

Exclusion criteria

• Have received treatment with an investigational drug, which has not received regulatory approval for any indication, within 28 days of study treatment with LY2874455
• Currently taking agents to control serum phosphate or calcium levels. This includes dietary restrictions
• Have medical conditions that, in the opinion of the investigator, would preclude participation in this study
• Have symptomatic central nervous system (CNS) malignancy or metastasis. Participants with treated CNS metastases are eligible provided their disease is radiographically stable, asymptomatic, and they are not currently receiving corticosteroids and/or anticonvulsants. Screening of asymptomatic participants without history of CNS metastases is not required
• Have a history of major organ transplant (for example: heart, lungs, liver, and kidney)
• Have current acute leukemia
• Females who are pregnant or nursing
• An untreated or uncontrolled acute infection, including urinary tract infection, within 7 days of study entry
• Have Bazett's corrected QT (QTcB) greater than 470 msec (female) or greater than 450 msec (male), history of unexplained recurrent syncope, history of congenital long QT syndrome, family history of sudden death, or the presence in the screening electrocardiogram (ECG) of a conduction abnormality that in the opinion of the investigator would preclude safe participation in this study
• Have had an autologous or allogenic bone marrow transplant
• Previously treated with LY2874455

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

94 participants in 12 patient groups

Part A: 2 mg FGF Receptor QD

Experimental group

Description:

Part A: Dose escalation 2 milligrams (mg) FGF receptor given orally once daily (QD) for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 4 mg FGF Receptor QD

Experimental group

Description:

Part A: Dose escalation 4 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 10 mg FGF Receptor QD

Experimental group

Description:

Part A: Dose escalation 10 mg FGF receptor given orally QD for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).

Treatment:

Drug: FGF Receptor

Part A: 10 mg FGF Receptor QD + Phosphate Binders

Experimental group

Description:

Part A: Dose escalation 10 mg FGF receptor + phosphate binders given QD for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: Phosphate Binders

Drug: FGF Receptor

Part A: 8 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 8 mg of FGF receptor given orally twice a day (BID) for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 10 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 10 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 14 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 14 FGF receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 18 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 18 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 24 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 24 mg FGF receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days).

Treatment:

Drug: FGF Receptor

Part A: 18 mg FGF Receptor BID Extension

Experimental group

Description:

Part A: Dose escalation 18 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part A: 16 mg FGF Receptor BID

Experimental group

Description:

Part A: Dose escalation 16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor

Part B: 16 mg FGF Receptor BID

Experimental group

Description:

Part B: Dose determined by part a dose escalation 16 mg FGF Receptor given orally BID for a minimum of (1) 28 day cycle. If participants are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)

Treatment:

Drug: FGF Receptor